Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 5Prostatic Neoplasms 2Lung Neoplasms 2Stomach Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 10Gemcitabine 8Cyclophosphamide 7Filgrastim 5Docetaxel 5Carboplatin 5Trastuzumab 4Surveys and Questionnaires 4Nivolumab 4Doxorubicin 4Cisplatin 4poly ICLC 3pazopanib 3atezolizumab 3aldesleukin 3Taxes 3Radiotherapy 3Paclitaxel 3Oncolytic Virotherapy 3Irinotecan 3Ipilimumab 3Injections 3Drug Therapy 3Cetuximab 3Capecitabine 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3spartalizumab 2palbociclib 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × lonafarnib × Breast × Clear all
NCT00288444 2012-12-18

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

Emory University

Phase 1 Terminated
38 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡